Navigation Links
Tocagen Appoints John Wood as Vice President, Regulatory Affairs and Quality Assurance
Date:2/16/2016

SAN DIEGO, Feb. 16, 2016 /PRNewswire/ -- Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced that John Wood has been named vice president of regulatory affairs and quality assurance. Mr. Wood holds more than 20 years of regulatory affairs experience focusing on first-in-class drugs for diseases with high unmet need. While at IDEC Pharmaceuticals he played a leading role, in close collaboration with Genentech, in the first regulatory approval of RITUXAN® for the treatment of immune system B-cell malignancies.

"John holds extensive experience in regulatory affairs activities, including overseeing drug approvals by the FDA and international regulatory agencies," said Harry Gruber, M.D., chief executive officer of Tocagen. "As Tocagen continues to enroll patients in Toca 5, our Phase 2/3 clinical trial in patients with recurrent high grade glioma, John's expertise and insights will be extremely beneficial."

Prior to joining Tocagen, Mr. Wood led regulatory affairs at Arena Pharmaceuticals, where he played an integral role interfacing with Eisai Inc. regarding regulatory strategy for life cycle management for BELVIQ®. Previous to this role Mr. Wood led regulatory affairs and alliance management at Amylin Pharmaceuticals, Inc., where he directed activities surrounding the first regulatory approvals of SYMLIN® and BYETTA® in the United States, served as program leader for BYETTA and acted as the primary interface with Eli Lilly. Prior to his position at Amylin Pharmaceuticals, Mr. Wood held regulatory leadership positions at Quintiles Consulting and Gensia, Inc. 

Mr. Wood holds a bachelor's degree in biology from University of California, San Diego and is Regulatory Affairs Certified by the Regulatory Affairs Professionals Society (RAPS).

About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer from within. The company is developing its lead investigational product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. More information about the clinical trial can be found at www.tocagen.com/toca5. In 2016, Tocagen plans to initiate clinical trials of Toca 511 & Toca FC in patients with newly diagnosed HGG and other solid tumors. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration, for Toca 511 & Toca FC for the treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma (GBM), a subset of HGG. For more information visit www.tocagen.com or follow @Tocagen.

Media Contact:
Monica May
Canale Communications
619-849-5383

 


'/>"/>
SOURCE Tocagen Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Tocagen Presents Interim Data from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology (SNO)
2. FDA Grants Fast Track Designation to Tocagens Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma
3. Tocagen Appoints Asha Das, M.D., as Vice President of Clinical Development
4. Tocagen Appoints Paul Schimmel, Ph.D., to the Board of Directors
5. Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagens Toca 511 & Toca FC, Compared to Published Benchmarks
6. Tocagen Expands Clinical Development Team;
7. Data Presented at Society for Neuro-Oncology Annual Meeting Demonstrate Tocagens Toca 511 Gene Therapy with Toca FC was Well Tolerated and Showed Antitumor Activity in Patients with High Grade Glioma
8. Six Presentations on Tocagens Toca 511 to be Given at the Society of Neuro-Oncology Annual Meeting
9. Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer
10. American Life Science Pharmaceuticals, Inc. (ALSP, Inc.) Appoints Col. (Retired) Dallas Hack, MD as Consultant
11. Insulet Appoints David A. Lemoine to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2020)... ... March 27, 2020 , ... Why a Podcast for Procap Medical Billing? , ... because she’d be able to explain more about what her business entails on a ... to learn more about the process of claim follow-up, conversing and networking with health ...
(Date:3/27/2020)... ... March 27, 2020 , ... ... Jonathan Chapman has been appointed as President and Chief Executive Officer. , Mr. ... recently serving as President of ARKRAY USA, Inc. He joins PTS Diagnostics with ...
(Date:3/22/2020)... ... ... Since 1988, Gwatney dealerships have strived to make car buying simple for ... COVID-19, Gwatney Mazda is pleased to announce two new services designed to ensure the ... , The dealership’s new Home Test Drives and Delivery service is a 100% online ...
Breaking Medicine Technology:
(Date:4/1/2020)... ... ... According to data released by Power to Decide , an estimated ... contraception live in counties impacted by the implementation of the Title X Family Planning ... of their Title X resources. , The domestic gag rule requires health ...
(Date:3/30/2020)... ... March 30, 2020 , ... Achieve Medical ... its commitment to provide comprehensive and compassionate mental health and wellness services in ... Center’s UpDox platform for telemedicine services including initial consultations, evaluations, and follow-up care. ...
(Date:3/28/2020)... BEACH, S.C. (PRWEB) , ... March 27, 2020 ... ... renowned orthopedic practice OrthoSC is now offering telemedicine as an alternative ... with one of the practice’s doctors in the comfort of their own home ...
(Date:3/27/2020)... LAKE MARY, Fla. (PRWEB) , ... March 27, 2020 , ... ... a three-month online educational health conference for people with asthma, their families and caregivers ... 24-hours a day between March 27, 2020 and June 30, 2020, and will focus ...
(Date:3/22/2020)... ... 21, 2020 , ... TriageLogic, a leader in telephone nurse ... health centers can use for patient care during the COVID-19 crisis. , ... working around the clock to implement emergency support solutions for patients who present ...
Breaking Medicine News(10 mins):